Genentech
Executive Summary
Issued patent "encompassing all forms of transforming growth factor beta made by recombinant technology," Genentech says Feb. 28. Genentech licenses the patent (5,284,763) from the National Institutes of Health. Genentech plans to begin Phase I trials of TGF-beta for mucositis associated with chemotherapy this year